These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24968896)

  • 1. An ovarian cancer model with positive ER: Reversion of ER antagonist resistance by Src blockade.
    Li L; Li X; Han X; Yang T; Fu J; Zhang Y; Gou W
    Oncol Rep; 2014 Sep; 32(3):943-50. PubMed ID: 24968896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
    Simpkins F; Hevia-Paez P; Sun J; Ullmer W; Gilbert CA; da Silva T; Pedram A; Levin ER; Reis IM; Rabinovich B; Azzam D; Xu XX; Ince TA; Yang JY; Verhaak RG; Lu Y; Mills GB; Slingerland JM
    Clin Cancer Res; 2012 Nov; 18(21):5911-23. PubMed ID: 22896656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
    Chen Y; Alvarez EA; Azzam D; Wander SA; Guggisberg N; Jordà M; Ju Z; Hennessy BT; Slingerland JM
    Breast Cancer Res Treat; 2011 Jul; 128(1):69-78. PubMed ID: 20669046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
    Sui M; Jiang D; Hinsch C; Fan W
    Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
    Simpkins F; Jang K; Yoon H; Hew KE; Kim M; Azzam DJ; Sun J; Zhao D; Ince TA; Liu W; Guo W; Wei Z; Zhang G; Mills GB; Slingerland JM
    Clin Cancer Res; 2018 Oct; 24(19):4874-4886. PubMed ID: 29959144
    [No Abstract]   [Full Text] [Related]  

  • 6. Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.
    Sonne-Hansen K; Norrie IC; Emdal KB; Benjaminsen RV; Frogne T; Christiansen IJ; Kirkegaard T; Lykkesfeldt AE
    Breast Cancer Res Treat; 2010 Jun; 121(3):601-13. PubMed ID: 19697122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.
    Hiscox S; Jordan NJ; Smith C; James M; Morgan L; Taylor KM; Green TP; Nicholson RI
    Breast Cancer Res Treat; 2009 May; 115(1):57-67. PubMed ID: 18493848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
    Li Z; Zhu Q; Chen H; Hu L; Negi H; Zheng Y; Ahmed Y; Wu Z; Li D
    Cancer Lett; 2016 Jul; 377(1):32-43. PubMed ID: 27063095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer.
    Argenta PA; Um I; Kay C; Harrison D; Faratian D; Sueblinvong T; Geller MA; Langdon SP
    Gynecol Oncol; 2013 Nov; 131(2):368-73. PubMed ID: 23911795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
    Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
    Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
    Herynk MH; Beyer AR; Cui Y; Weiss H; Anderson E; Green TP; Fuqua SA
    Mol Cancer Ther; 2006 Dec; 5(12):3023-31. PubMed ID: 17172405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.
    Jain S; Wang X; Chang CC; Ibarra-Drendall C; Wang H; Zhang Q; Brady SW; Li P; Zhao H; Dobbs J; Kyrish M; Tkaczyk TS; Ambrose A; Sistrunk C; Arun BK; Richards-Kortum R; Jia W; Seewaldt VL; Yu D
    Cancer Res; 2015 Nov; 75(22):4863-75. PubMed ID: 26383165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
    Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
    Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.
    Nakachi I; Helfrich BA; Spillman MA; Mickler EA; Olson CJ; Rice JL; Coldren CD; Heasley LE; Geraci MW; Stearman RS
    Clin Transl Sci; 2016 Dec; 9(6):293-301. PubMed ID: 27766744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
    Hew KE; Miller PC; El-Ashry D; Sun J; Besser AH; Ince TA; Gu M; Wei Z; Zhang G; Brafford P; Gao W; Lu Y; Mills GB; Slingerland JM; Simpkins F
    Clin Cancer Res; 2016 Feb; 22(4):935-47. PubMed ID: 26482043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer.
    Wang L; Yu X; Dong J; Meng Y; Yang Y; Wang H; Wang C; Zhang Y; Zhao Y; Zhao J; Wang H; Lu C; Li B
    Biochem Biophys Res Commun; 2016 Oct; 479(3):563-570. PubMed ID: 27666484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer.
    Chan KK; Leung TH; Chan DW; Wei N; Lau GT; Liu SS; Siu MK; Ngan HY
    J Endocrinol; 2014 May; 221(2):325-36. PubMed ID: 24819599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells.
    Hall JM; Korach KS
    Mol Endocrinol; 2003 May; 17(5):792-803. PubMed ID: 12586845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
    Fang H; Jin J; Huang D; Yang F; Guan X
    Cancer Sci; 2018 Jun; 109(6):1949-1957. PubMed ID: 29601121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
    O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.